Aquaflor
- Manufacturer
- Merck Sharp & Dohme Corp.
- Effective date
- 2025-09-25
- Label type
- VFD TYPE A MEDICATED ARTICLE ANIMAL DRUG LABEL
- Version
- 10
- Source
- full-release
- Hydrated at
- 2026-06-01 02:45:02
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
SPL UNCLASSIFIED SECTION
Type A Medicated Article
For Use in Freshwater-reared Finfish Feeds Only
| Do Not Feed Undiluted |
CAUTION
Federal law restricts medicated feed containing this veterinary feed directive (VFD) drug to use by or on the order of a licensed veterinarian.
Active Drug Ingredient
Florfenicol 500 g per kg (227.27 g per lb)
Inert ingredients
Lactose and Povidone.
Description
Each kg of Aquaflor® (florfenicol) contains 500 g (1.1 lb) of florfenicol in a palatable base.
Indications
| Fish Species | Indication | Florfenicol (mg/kg body weight/day) | Florfenicol (grams/ton) |
|---|---|---|---|
| Caution: Not for use in animals intended for breeding purposes. The effects of florfenicol on reproductive performance have not been determined. Toxicity studies in dogs, rats, and mice have associated the use of florfenicol with testicular degeneration and atrophy. For catfish, a dose related decrease in hematopoietic/lymphopoietic tissue may occur. The time required for the hematopoietic/lymphopoietic tissues to regenerate was not evaluated. | |||
| Freshwater-reared salmonids | For the control of mortality due to furunculosis associated with Aeromonas salmonicida. | 10 - 15 | 182-2,724 |
| For the control of mortality due to coldwater disease associated with Flavobacterium psychrophilum. | |||
| Freshwater-reared finfish | For the control of mortality due to columnaris disease associated with Flavobacterium columnare. | 10 - 15 | 182-2,724 |
| Catfish | For the control of mortality due to enteric septicemia of catfish associated with Edwardsiella ictaluri. | 10 - 15 | 182-2,724 |
| Freshwater-reared warmwater finfish | For the control of mortality due to streptococcal septicemia associated with Streptococcus iniae. | 15 | 273- 2,724 |
RESIDUE WARNING
Feeds containing Aquaflor® (florfenicol) must be withdrawn 15 days prior to slaughter.
IMPORTANT
This product has been evaluated in salmonid and catfish feeds and should be used in feeds nutritionally similar to these evaluated feeds. Refer to the Freedom of Information Summary for details. Must be thoroughly mixed in feeds or surface-coated (top-coated) onto the feeds before use.
Mixing Instructions
SPL UNCLASSIFIED SECTION
For incorporation into feed pellets: For making Aquaflor® (florfenicol) Type C Medicated Feed:
- Aquaflor® (florfenicol) is added to other feed ingredients in the mixer prior to extrusion,
- the ingredients are mixed thoroughly to insure homogeneity,
- the mixture is steam pelleted or extruded and pellets are dried,
- medicated feed pellets are mixed/coated with a predetermined amount of fish or vegetable oil, and
- at the completion of mixing, the product is transferred to a storage tank for packaging or transport.
SPL UNCLASSIFIED SECTION
For surface-coating (top-coating) onto feed pellets: There are two methods for making Aquaflor® (florfenicol) Type C Medicated Feed by top-coating.
Method 1:
- add a known quantity of fish feed into a mixer,
- weigh out Aquaflor® (florfenicol),
- mix Aquaflor® with feed pellets,
- medicated feed pellets are mixed/coated with a predetermined amount of fish or vegetable oil, and
- at the completion of mixing, the product is transferred to a storage tank for packaging or transport.
Method 2:
- weigh out fish oil or vegetable oil into a bucket,
- weigh out Aquaflor® (florfenicol) and mix thoroughly with the oil in the bucket,
- add a known quantity of fish feed into a mixer,
- add the Aquaflor® (florfenicol) and oil mixture to the feed in the mixer, slowly, while the mixer is running at low speed,
- at the completion of mixing, the product is transferred to a storage tank for packaging or transport.
SPL UNCLASSIFIED SECTION
| Feeding Rate | Florfenicol Concentration in Feed | Amount of Aquaflor® (florfenicol) per Ton of Feed | Biomass of Fish Medicated per Ton of Feed per 10-day Treatment Period | ||
|---|---|---|---|---|---|
| % Biomass | Grams/ton | lbs | lbs | ||
| Dose 10 mg/kg | Dose 15 mg/kg | Dose 10 mg/kg | Dose 15 mg/kg | ||
| 0.5 | 1,816 | 2,724 | 8 | 12 | 40,000 |
| 1 | 908 | 1,362 | 4 | 6 | 20,000 |
| 2 | 454 | 681 | 2 | 3 | 10,000 |
| 3 | 300 | 450 | 1.32 | 1.98 | 6,666 |
| 5 | 182 | 273 | 0.8 | 1.2 | 4,000 |
Feeding Directions
Feed as the sole ration for 10 consecutive days. Aquaflor® (florfenicol) medicated feed should only be administered once disease has been appropriately diagnosed. Feeding fish at a percent of biomass and corresponding florfenicol concentration included in the table above will deliver the appropriate florfenicol dose.
Caution
Feed containing Aquaflor® (florfenicol) shall not be fed to finfish for more than 10 days. Following administration, fish should be re-evaluated by a licensed veterinarian before initiating a further course of therapy. The expiration date for VFD for Aquaflor® (florfenicol) must not exceed 6 months from the date of issuance. VFD for Aquaflor® (florfenicol) shall not be refilled.
Sunburn, skin lesions, and skin sloughing have been reported in salmonids treated with florfenicol. Not all adverse drug events are reported to FDA CVM. It is not always possible to reliably estimate the adverse event incidence or to establish a causal relationship to product exposure using this data alone.
Before using this drug for the first time, you must inform the appropriate National Pollutant Discharge Elimination System (NPDES) permitting authority of your intentions and of the following information. Acute and chronic water quality benchmarks for the protection of freshwater aquatic life have been derived by FDA for florfenicol following EPA guidance for calculating Tier II water quality criteria for the Great Lakes System (40 CFR 132, App. A). The acute benchmark value (Secondary Maximum Concentration) is 20.6 mg/L (equivalent to one-half of the Secondary Acute Value). The chronic benchmark value (Secondary Continuous Concentration) is 0.23 mg/L (equivalent to the Final Plant Value). The NPDES authority may require an NPDES permit before you can discharge Aquaflor®. The water quality benchmark concentrations are not discharge limits, but may be used by the NPDES authority to derive such limits for the permit. Additional environmental information on Aquaflor® and the benchmark values are available in an environmental assessment posted at
animaldrugsatfda.fda.gov/adafda/views/#/environmentalAssessments
WARNING
Avoid inhalation, oral exposure, and direct contact with skin or eyes. Operators mixing and handling Aquaflor® (florfenicol) should use protective clothing, gloves, goggles and NIOSH-approved dust mask. Wash thoroughly with soap and water after handling. If accidental eye contact occurs, immediately rinse thoroughly with water. If irritation persists, seek medical attention. Not for human consumption. Keep out of reach of children. The Safety Data Sheet (SDS) contains more detailed occupational safety information. For more information or to report adverse effects, call 1-800-224-5318. For customer service, call 1-800-521-5767. For a copy of SDS sheet, call 1-800-770-8878.
STORAGE CONDITIONS
Store at temperatures up to 25°C with excursions permitted to 40°C.
SPL UNCLASSIFIED SECTION
Approved by FDA under NADA # 141-246
Copyright © 2013 - 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
Formulated in Austria.
Rev. 6/2022
LOT:
EXP:
354296 R4
PRINCIPAL DISPLAY PANEL - 2 kg Pouch Label
2 kg (4.4 lb)
Aquaflor®
(Florfenicol)
Type A Medicated Article
For Use in Freshwater-reared Finfish Feeds Only
Do Not Feed Undiluted
CAUTION: Federal law restricts medicated feed containing this veterinary feed directive
(VFD) drug to use by or on the order of a licensed veterinarian.
Active Drug Ingredient: Florfenicol 500 g per kg (227.27 g per lb)
Description: Each kg of Aquaflor® (florfenicol) contains 500 g (1.1 lb)
of florfenicol in a palatable base.
Approved by FDA under NADA # 141-246
Copyright © 2013 - 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
Florfenicol (active ingred.) made in China. Formulated in Austria.
Rev. 6/2022
MERCK
Animal Health
368029 R4

DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 0061-1355-01 | AquaflorType A Medicated Article | 2 kg in 1 POUCH | POWDER | 2 | 10 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| florfenicol | ACTIVE INGREDIENT | 9J97307Y1H | 5 | |
| florfenicol | ACTIVE MOIETY | 9J97307Y1H | 5 | |
| Lactose Monohydrate | INACTIVE INGREDIENT | EWQ57Q8I5X | 5 | |
| Povidones | INACTIVE INGREDIENT | FZ989GH94E | 5 |
Products#
Every source-derived product name is available through these pages.
- Aquaflor Type A Medicated Article
- florfenicol
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 0061-1355 | 0061-1355-01 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| FLORFENICOL | 9J97307Y1H | ACTIB |
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Povidones | POVIDONE | FZ989GH94E | SUSPENSION/ DROPS / OPHTHALMIC | 0.6 %w/v | ||
| Povidones | POVIDONE | FZ989GH94E | TABLET / SUBLINGUAL | 6 mg | ||
| Lactose Monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVERNOUS | 174 mg | ||
| Lactose Monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET, FOR SUSPENSION / ORAL | 2794 mg | ||
| Lactose Monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | PELLET / ORAL | 640 mg | ||
| Lactose Monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 214 mg | ||
| Povidones | POVIDONE | FZ989GH94E | POWDER, FOR SUSPENSION / ORAL | 35 mg/5ml | ||
| Povidones | POVIDONE | FZ989GH94E | CAPSULE, COATED PELLETS / ORAL | 10.03 mg | ||
| Lactose Monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 520 mg | ||
| Povidones | POVIDONE | FZ989GH94E | SUSPENSION / OPHTHALMIC | 1.8 %w/v | ||
| Povidones | POVIDONE | FZ989GH94E | SUSPENSION / ORAL | 20 mg/5ml | ||
| Povidones | POVIDONE | FZ989GH94E | TABLET, COATED / ORAL | 49.2 mg | ||
| Lactose Monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | POWDER / RESPIRATORY (INHALATION) | 25 mg | ||
| Povidones | POVIDONE | FZ989GH94E | TABLET, DELAYED RELEASE / ORAL | 53 mg | ||
| Povidones | POVIDONE | FZ989GH94E | TABLET, ORALLY DISINTEGRATING / ORAL | 15.03 mg | ||
| Lactose Monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | GRANULE, FOR SOLUTION / ORAL | 1691.8 mg/120ml | ||
| Povidones | POVIDONE | FZ989GH94E | TABLET / ORAL | 216 mg | ||
| Lactose Monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET / SUBLINGUAL | 505 mg | ||
| Povidones | POVIDONE | FZ989GH94E | CAPSULE, DELAYED RELEASE / ORAL | NA | ||
| Povidones | POVIDONE | FZ989GH94E | INJECTION / INTRAMUSCULAR | 0.2 %w/v | ||
| Lactose Monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | CAPSULE, DELAYED RELEASE / ORAL | 2087 mg | ||
| Povidones | POVIDONE | FZ989GH94E | TROCHE / ORAL | 30 mg | ||
| Povidones | POVIDONE | FZ989GH94E | IMPLANT / SUBCUTANEOUS | 6 mg | ||
| Lactose Monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION / INTRAVENOUS | 900 mg | ||
| Lactose Monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | CAPSULE, EXTENDED RELEASE / ORAL | 5364 mg | ||
| Lactose Monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | POWDER, FOR SUSPENSION / ORAL | NA | ||
| Povidones | POVIDONE | FZ989GH94E | CAPSULE, DELAYED RELEASE PELLETS / ORAL | 32 mg | ||
| Povidones | POVIDONE | FZ989GH94E | SOLUTION / ORAL | 3000 mg | ||
| Lactose Monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET, FILM COATED / ORAL | 968 mg | ||
| Povidones | POVIDONE | FZ989GH94E | SOLUTION / OPHTHALMIC | 1.8 %w/v | ||
| Lactose Monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 214 mg | ||
| Lactose Monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | CAPSULE, COATED / ORAL | 300 mg | ||
| Lactose Monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION / INTRAMUSCULAR | 150 mg | ||
| Povidones | POVIDONE | FZ989GH94E | TABLET, EXTENDED RELEASE / ORAL | 101 mg | ||
| Lactose Monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 690 mg | ||
| Lactose Monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 107 mg | ||
| Povidones | POVIDONE | FZ989GH94E | CAPSULE / ORAL | 300 mg | ||
| Lactose Monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET / BUCCAL | 43 mg | ||
| Lactose Monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INSERT / VAGINAL | 2282 mg | ||
| Povidones | POVIDONE | FZ989GH94E | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 350 mg | ||
| Povidones | POVIDONE | FZ989GH94E | SUSPENSION / AURICULAR (OTIC) | NA | ||
| Povidones | POVIDONE | FZ989GH94E | TABLET, FILM COATED / ORAL | 240 mg | ||
| Lactose Monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET, EXTENDED RELEASE / ORAL | 2575 mg | ||
| Povidones | POVIDONE | FZ989GH94E | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| Povidones | POVIDONE | FZ989GH94E | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 17 mg | ||
| Povidones | POVIDONE | FZ989GH94E | TABLET, CHEWABLE / ORAL | 48 mg | ||
| Lactose Monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVITARY | 47.5 mg | ||
| Lactose Monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 9.5 %w/v | ||
| Lactose Monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET / ORAL | 4384 mg | ||
| Lactose Monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET, DELAYED RELEASE / ORAL | 2313 mg | ||
| Lactose Monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 750 mg | ||
| Lactose Monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET, ORALLY DISINTEGRATING / ORAL | 366 mg | ||
| Lactose Monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | CREAM / VAGINAL | 586 mg | ||
| Povidones | POVIDONE | FZ989GH94E | TABLET, FOR SUSPENSION / ORAL | 2 mg | ||
| Povidones | POVIDONE | FZ989GH94E | DROPS / ORAL | NA | ||
| Lactose Monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | CAPSULE / ORAL | 3990 mg | ||
| Lactose Monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET, COATED / ORAL | 1301 mg | ||
| Povidones | POVIDONE | FZ989GH94E | CAPSULE, EXTENDED RELEASE / ORAL | 56 mg | ||
| Lactose Monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | GRANULE, FOR SUSPENSION / ORAL | NA | ||
| Lactose Monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | GRANULE / ORAL | 8946 mg |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.

